Company / Cash & Equivalents
Chemed Corp. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$74.5M
FY2025
5-year range
$32.9M / $264.0M
FY2021-FY2025
Trend
-58.2%
vs FY2024
Sector context
#126 of 152
Health Care
What the data says
Chemed Corp.'s cash & equivalents of $75M is lower than 83% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $5M in FY2018 to $264M in FY2023.
Based on SEC 10-K filings.
$75M in FY2025 with a 5-year CAGR of -14.5%.
Declined from $264M to $75M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +0.2%
- 5-Year CAGR
- -14.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 152This company $74.5M Sector average $1.2B
▼
-93.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.5%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 58.2% year-over-year.
- Ranks #126 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 4.70 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.5M | -58.2% |
| FY2024 | $178.3M | -32.4% |
| FY2023 | $264.0M | +256.1% |
| FY2022 | $74.1M | +125.3% |
| FY2021 | $32.9M | -79.8% |
| FY2020 | $162.7M | +2541.7% |
| FY2019 | $6.2M | +27.5% |
| FY2018 | $4.8M | -56.6% |
| FY2017 | $11.1M | -27.4% |
| FY2016 | $15.3M | +4.0% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026